Advisors Preferred LLC Increases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Advisors Preferred LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 31.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 55,536 shares of the biopharmaceutical company's stock after purchasing an additional 13,374 shares during the quarter. Advisors Preferred LLC's holdings in Halozyme Therapeutics were worth $3,436,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the business. Bessemer Group Inc. boosted its stake in Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 207 shares during the last quarter. Heck Capital Advisors LLC bought a new position in Halozyme Therapeutics in the fourth quarter valued at approximately $29,000. Park Place Capital Corp lifted its stake in Halozyme Therapeutics by 20.1% in the first quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company's stock valued at $69,000 after buying an additional 182 shares in the last quarter. UMB Bank n.a. lifted its stake in Halozyme Therapeutics by 267.4% in the first quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company's stock valued at $84,000 after buying an additional 960 shares in the last quarter. Finally, CWM LLC lifted its stake in Halozyme Therapeutics by 46.3% in the first quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company's stock valued at $88,000 after buying an additional 438 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on HALO. JPMorgan Chase & Co. lifted their price target on shares of Halozyme Therapeutics from $58.00 to $60.00 and gave the company a "neutral" rating in a research note on Wednesday, July 16th. The Goldman Sachs Group began coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They issued a "neutral" rating and a $55.00 price objective on the stock. Wells Fargo & Company lifted their price objective on shares of Halozyme Therapeutics from $60.00 to $65.00 and gave the company an "equal weight" rating in a report on Wednesday, May 7th. Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a report on Tuesday, May 13th. Finally, Morgan Stanley downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $73.00 to $62.00 in a report on Wednesday, May 14th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $62.70.

Halozyme Therapeutics Price Performance

HALO traded down $0.53 on Friday, hitting $58.24. 820,842 shares of the stock were exchanged, compared to its average volume of 1,936,019. Halozyme Therapeutics, Inc. has a 12 month low of $42.01 and a 12 month high of $70.50. The business has a 50-day moving average of $54.63 and a two-hundred day moving average of $57.46. The company has a debt-to-equity ratio of 3.13, a current ratio of 8.39 and a quick ratio of 7.30. The firm has a market capitalization of $7.18 billion, a price-to-earnings ratio of 15.49, a PEG ratio of 0.39 and a beta of 1.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.13. The business had revenue of $264.86 million during the quarter, compared to analysts' expectations of $231.21 million. Halozyme Therapeutics had a net margin of 44.76% and a return on equity of 136.91%. Halozyme Therapeutics's revenue was up 35.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.79 earnings per share. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 4,497 shares of the stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $60.37, for a total transaction of $271,483.89. Following the transaction, the director directly owned 28,611 shares in the company, valued at approximately $1,727,246.07. This represents a 13.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00. Following the transaction, the chief executive officer owned 733,719 shares in the company, valued at $41,403,763.17. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 64,497 shares of company stock valued at $3,533,884 in the last three months. Insiders own 2.40% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.